Mersana Therapeutics's total assets for Q4 2024 were $144.66M, a decrease of -14.67% from the previous quarter. MRSN total liabilities were $154.17M for the fiscal quarter, a -8.49% a decrease from the previous quarter. See a summary of the company’s assets, liabilities, and equity.